Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience

Oncotarget

Volumn 5, Issue 22, 2014, Pages 11168-11179

  Hou, Ming Mo ^a,c   Liu, Xiaochun ^a   Wheler, Jennifer ^a   Naing, Aung ^a   Hong, David ^a   Coleman, Robert L ^a   Tsimberidou, Apostolia ^a   Janku, Filip ^a   Zinner, Ralph ^a   Lu, Karen ^a   Kurzrock, Razelle ^b   Fu, Siqing ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

Cervical cancer; Matched therapy; Phase i trial; PIK3CA mutation; PTEN loss

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; AURORA KINASE INHIBITOR; BENDAMUSTINE; BEVACIZUMAB; BEVACIZUMAB PLUS GEMCITABINE; CAPECITABINE; CARBOPLATIN; CARBOPLATIN PLUS PACLITAXEL; DENOSUMAB; DOCETAXEL; DOXIL PLUS TEMSIROLIMUS; ERLOTINIB; EVEROLIMUS; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN; METFORMIN; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; OXALIPLATIN; PACLITAXEL; PAZOPANIB; PEMETREXED; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PRALATREXATE; PROTEASOME INHIBITOR; PROTEIN KINASE B; RAPAMYCIN; TEMSIROLIMUS; TRIENTINE; UNCLASSIFIED DRUG; MTOR PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PIK3CA PROTEIN, HUMAN; PTEN PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; BACTERIAL INFECTION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; DRUG EFFICACY; FATIGUE; FEMALE; GENE; GENE LOSS; GENE MUTATION; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; INTESTINE PERFORATION; MAJOR CLINICAL STUDY; MIDDLE AGED; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; NEUTROPENIA; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PIK3CA GENE; PROGRESSION FREE SURVIVAL; PTEN GENE; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; UTERINE CERVIX CARCINOMA; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CLINICAL TRIAL; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PHASE 1 CLINICAL TRIAL; UTERINE CERVICAL NEOPLASMS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; FEMALE; HUMANS; MIDDLE AGED; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; TOR SERINE-THREONINE KINASES; UTERINE CERVICAL NEOPLASMS;

EID: 84917710610     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2584     Document Type: Article

References (40)

1. Forouzanfar MH, Foreman KJ, Delossantos AM, Lozano R, Lopez AD, Murray CJ, Naghavi M. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet. 2011; 378:1461-1484.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA: a cancer journal for clinicians. 2014; 64:9-29.
3. Grisaru D, Covens A, Chapman B, Shaw P, Colgan T, Murphy J, DePetrillo D, Lickrish G, Laframboise S, Rosen B. Does histology influence prognosis in patients with early-stage cervical carcinoma?. Cancer. 2001; 92:2999-3004.
4. Undurraga M, Loubeyre P, Dubuisson JB, Schneider D, Petignat P. Early-stage cervical cancer: is surgery better than radiotherapy? Expert Rev Anticancer Ther. 2010; 10:451-460.
5. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26:5802-5812.
6. Long HJ 3rd, Bundy BN, Grendys EC, Jr., Benda JA, McMeekin DS, Sorosky J, Miller DS, Eaton LA, Fiorica JV. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005; 23:4626-4633.
7. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, Benda J, Cella D. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol. 2009; 27:4649-4655.
8. Barbera L, Thomas G. Management of early and locally advanced cervical cancer. Semin Oncol. 2009; 36:155-169.
9. Tewari KS, Monk BJ. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group. Semin Oncol. 2009; 36:170-180.
10. Tewari KS, Sill MW, Long HJ 3rd, Penson RT, Huang H, Ramondetta LM, Landrum LM, Oaknin A, Reid TJ, Leitao MM, Michael HE, Monk BJ. Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med. 2014; 370:734-743.
11. Movva S, Rodriguez L, Arias-Pulido H, Verschraegen C. Novel chemotherapy approaches for cervical cancer. Cancer. 2009; 115:3166-3180.
12. Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Molecularly targeted therapies in cervical cancer. A systematic review. Gynecol Oncol. 126:291-303.
13. Duenas-Gonzalez A, Cetina L, Coronel J, Cervantes-Madrid D. Emerging drugs for cervical cancer. Expert Opin Emerg Drugs. 17:203-218.
14. Wee S, Lengauer C, Wiederschain D. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development. Current opinion in oncology. 2008; 20:77-82.
15. Ma YY, Wei SJ, Lin YC, Lung JC, Chang TC, Whang-Peng J, Liu JM, Yang DM, Yang WK, Shen CY. PIK3CA as an oncogene in cervical cancer. Oncogene. 2000; 19:2739-2744.
16. German S, Aslam HM, Saleem S, Raees A, Anum T, Alvi AA, Haseeb A. Carcinogenesis of PIK3CA. Hereditary cancer in clinical practice. 2013; 11:5.
17. Zhang S, Yu D. PI(3)king apart PTEN's role in cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2010; 16:4325-4330.
18. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF. The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Current cancer drug targets. 2008; 8:187-198.
19. Kim KW, Myers CJ, Jung DK, Lu B. NVP-BEZ-235 enhances radiosensitization via blockade of the PI3K/ mTOR pathway in cisplatin-resistant non-small cell lung carcinoma. Genes & cancer. 2014; 5:293-302.
20. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R. Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res. 2012; 18:6373-6383.
21. Hou MM, Wheler J, Hong D, Naing A, Tsimberidou A, Janku F, Zinner R, Piha-Paul S, Falchook G, Kurzrock R, Fu S. Phase I Clinical Experience of Patients with Cervical Cancer. Anticancer Res. 2014.
22. Bertelsen BI, Steine SJ, Sandvei R, Molven A, Laerum OD. Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation. International journal of cancer Journal international du cancer. 2006; 118:1877-1883.
23. Cui B, Zheng B, Zhang X, Stendahl U, Andersson S, Wallin KL. Mutation of PIK3CA: possible risk factor for cervical carcinogenesis in older women. International journal of oncology. 2009; 34:409-416.
24. McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, Ghatage P, Magliocco AM, Doll CM. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecologic oncology. 2013; 128:409-414.
25. Henken FE, Banerjee NS, Snijders PJ, Meijer CJ, De-Castro Arce J, Rosl F, Broker TR, Chow LT, Steenbergen RD. PIK3CA-mediated PI3-kinase signalling is essential for HPV-induced transformation in vitro. Molecular cancer. 2011; 10:71.
26. Cancer Therapy Evaluation Program NCI [16 April 2013];Common Terminology Criteria for Adverse events (CTCAE): http://ctep.cancer.gov/protocolDevelopment/ electronic_applications/ctc.htm.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92:205-216.
28. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009; 45:228-247.
29. Tao X, Hu W, Ramirez PT, Kavanagh JJ. Chemotherapy for recurrent and metastatic cervical cancer. Gynecol Oncol. 2008; 110:S67-71.
30. Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM. Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Int J Gynecol Cancer. 2007; 17:1194-1204.
31. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. Cell Rep. 2014; 6:377-387.
32. Lu D, Qian J, Yin X, Xiao Q, Wang C, Zeng Y. Expression of PTEN and survivin in cervical cancer: promising biological markers for early diagnosis and prognostic evaluation. Br J Biomed Sci. 2013; 69:143-146.
33. Bourmenskaya O, Shubina E, Trofimov D, Rebrikov D, Sabdulaeva E, Nepsha O, Bozhenko V, Rogovskaya S, Sukhikh G. Host gene expression profiling of cervical smear is eligible for cancer risk evaluation. J Clin Pathol. 2013; 66:282-285.
34. Vazquez-Ulloa E, Lizano M, Aviles-Salas A, Alfaro-Moreno E, Contreras-Paredes A. Abnormal distribution of hDlg and PTEN in premalignant lesions and invasive cervical cancer. Gynecol Oncol. 2011; 122:663-668.
35. Eijsink JJ, Noordhuis MG, ten Hoor KA, Kok M, Hollema H, de Bock GH, Nijman HW, Schuuring E, Wisman GB, van der Zee AG. The epidermal growth factor receptor pathway in relation to pelvic lymph node metastasis and survival in early-stage cervical cancer. Hum Pathol. 2010; 41:1735-1741.
36. McIntyre JB, Wu JS, Craighead PS, Phan T, Kobel M, Lees-Miller SP, Ghatage P, Magliocco AM, Doll CM. PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy. Gynecol Oncol. 2012; 128:409-414.
37. Janku F, Wheler JJ, Naing A, Falchook GS, Hong DS, Stepanek VM, Fu S, Piha-Paul SA, Lee JJ, Luthra R, Tsimberidou AM, Kurzrock R. PIK3CA mutation H1047R is associated with response to PI3K/AKT/mTOR signaling pathway inhibitors in early-phase clinical trials. Cancer Res. 2013; 73:276-284.
38. Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, Tsimberidou AM, Fu S, Falchook GS, Hong DS, Garrido-Laguna I, Luthra R, Lee JJ, Lu KH, Kurzrock R. PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30:777-782.
39. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R. PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Molecular cancer therapeutics. 2011; 10:558-565.
40. Edgar KA, Crocker L, Cheng E, Wagle MC, Wongchenko M, Yan Y, Wilson TR, Dompe N, Neve RM, Belvin M, Sampath D, Friedman LS, Wallin JJ. Amphiregulin and PTEN evoke a multimodal mechanism of acquired resistance to PI3K inhibition. Genes & cancer. 2014; 5:113-126.